INmune Bio, Inc. (INMB)

INmune Bio Stock Forecast

Stock Price Forecast

According to 3 professional analysts, the 12-month price target for INmune Bio stock ranges from a low of $0.60 to a high of $20. The average analyst price target of $9.53 forecasts a 272.27% increase in the stock price over the next year.

Price Target: $9.53 (+272.27%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$0.60	$9.53	$8.00	$20
Change	-76.56%	+272.27%	+212.50%	+681.25%

* Price targets were last updated on Jul 2, 2025.

Analyst Ratings

The average analyst rating for INmune Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	2	2	2	2	2	2
Buy	1	1	1	1	0	0
Hold	0	0	0	0	1	1
Sell	0	0	0	0	1	1
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Maintains $30 → $8	Strong Buy	Maintains	$30 → $8	+212.50%	Jul 2, 2025
Thomas Shrader BTIG	BTIG	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Jul 1, 2025
George Farmer Scotiabank	Scotiabank	Buy → Sell Downgrades $23 → $0.6	Buy → Sell	Downgrades	$23 → $0.6	-76.56%	Jul 1, 2025
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Maintains $22 → $30	Strong Buy	Maintains	$22 → $30	+1,071.88%	Feb 13, 2025
George Farmer Scotiabank	Scotiabank	Buy Maintains $22 → $23	Buy	Maintains	$22 → $23	+798.44%	Feb 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

43.72K

Increased by 212.27%

from 14.00K

Revenue Next Year

4.50M

Increased by 10,184.28%

from 43.72K

EPS This Year

-1.59

from -2.11

EPS Next Year

-1.41

from -1.59

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	11.00K	181.00K	374.00K	155.00K	14.00K	43.72K	4.50M	13.07M
Revenue Growth	-	1,545.46%	106.63%	-58.56%	-90.97%	212.27%	10,184.28%	190.75%
EPS	-1.01	-1.88	-1.52	-1.67	-2.11	-1.59	-1.41	-1.30
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	8	8	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	105,000	15.2M	24.8M
Avg	43,717	4.5M	13.1M
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	650.0%	34,577.4%	451.2%
Avg	212.3%	10,184.3%	190.7%
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-1.49	-0.53	-0.83
Avg	-1.59	-1.41	-1.30
Low	-1.81	-2.11	-1.62

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.